Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Equity Average (2016 - 2025)

Amicus Therapeutics filings provide 15 years of Equity Average readings, the most recent being $252.3 million for Q4 2025.

  • On a quarterly basis, Equity Average rose 35.35% to $252.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $252.3 million, a 35.35% increase, with the full-year FY2025 number at $234.1 million, up 32.2% from a year prior.
  • Equity Average hit $252.3 million in Q4 2025 for Amicus Therapeutics, up from $217.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $342.0 million in Q4 2021 to a low of $107.1 million in Q2 2023.
  • Median Equity Average over the past 5 years was $190.1 million (2024), compared with a mean of $193.4 million.
  • Biggest five-year swings in Equity Average: tumbled 62.63% in 2022 and later surged 51.15% in 2025.
  • Amicus Therapeutics' Equity Average stood at $342.0 million in 2021, then tumbled by 62.63% to $127.8 million in 2022, then grew by 14.79% to $146.7 million in 2023, then rose by 27.08% to $186.4 million in 2024, then soared by 35.35% to $252.3 million in 2025.
  • The last three reported values for Equity Average were $252.3 million (Q4 2025), $217.4 million (Q3 2025), and $198.9 million (Q2 2025) per Business Quant data.